Edgewise Therapeutics : Corporate Presentation

A Novel Approach to Tackling

Rare Progressive Muscle Disorders

Corporate Presentation

November 2022

Disclaimer

This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's drug discovery platform, and Edgewise's product candidates and programs, including EDG-5506 and EDG-002; the expected milestones and timing of such milestones for EDG-5506 including the expected timing of reporting of data for EDG-5506 and initiation of planned clinical trials; the expected milestones and timing of such milestones for EDG-002; statements regarding the market opportunity for Edgewise's product candidates; statements regarding Edgewise's pipeline of product candidates and programs; statements regarding the potential for EDG-5506 to be combined with other therapeutics and the potential of EDG-5506 in other myopathies; and statements regarding Edgewise's financial position including its liquidity and the sufficiency of its cash and cash equivalents. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially" "will" or the negative of these terms or other similar expressions.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: negative impacts of the COVID-19 pandemic on Edgewise's operations, including clinical trials; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; Edgewise's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates or research programs; changes in Edgewise's plans to develop and commercialize EDG-5506,EDG-002 or any other product candidates or research programs; the potential for clinical trials of EDG-5506 or any other product candidates to differ from preclinical, interim, preliminary, topline or expected results; Edgewise's ability to enroll patients in its ongoing and future clinical trials; Edgewise's ability to raise funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Edgewise's reliance on third parties, including contract manufacturers and contract research organizations; Edgewise's ability to obtain and maintain intellectual property protection for its product candidates; risks associated with access to capital and credit markets; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise's ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Edgewise files from time to time with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

				2
			2

Edgewise Therapeutics is a Clinical-Stage Company Focused on Advancing Innovative Treatments for Severe, Rare Muscle Disorders

Developing EDG-5506 to become the foundational therapy for muscular dystrophies

Leveraging our discovery and development capabilities to advance additional programs

Plan to enhance portfolio from internal research and external business development

Experienced management team with deep expertise in muscle physiology/rare diseases

Our vision is to improve the lives of patients and families suffering from rare muscle disorders

				3
			3

We Focus Our Small Molecule Precision Platform on Discovering Novel Disease Modifying Therapies for Inherited Muscle Disorders

Intimate Familiarity with Muscle

Biophysics/Integrated Physiology

Proven In-House Discovery Scientists	Combining High-Throughput Assays with
Biophysical and Selectivity Screening
and Clinical Experts
Systems

Deep Expertise in Advanced Animal Models of

Human Genetic Muscle Diseases

4

Our Precision Medicine Muscle Platform has Generated One Clinical Stage Program and Multiple Research Programs

Program	Target	Indications	Preclinical Phase 1	Phase 2	Phase 3
EDG-5506	Skeletal Muscle	DMD
Myosin ATPase
EDG-5506	Skeletal Muscle	BMD
Myosin ATPase
EDG-5506	Skeletal Muscle	LGMD, McArdle
Myosin ATPase
EDG-5506	Skeletal Muscle	BMD	ARCH Open Label Study Ongoing
Myosin ATPase
EDG-002	Cardiac Muscle	HCM
Undisclosed Target

Abbreviations: BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; LGMD, limb-girdle muscular dystrophy; HCM, hypertrophic cardiomyopathy

				5
			5